Pulmonx
Jim Outlaw has a diverse work experience in the healthcare and sales industries. Jim started their career at Cintas Corporation in 2002 as a Sales Manager and worked there until 2009. Following that, they joined Boston Scientific as a Territory Manager and Sales Trainer, holding the position for nine years. In 2018, they transitioned to Pulmonx Corporation, initially serving as a Territory Manager before being promoted to Regional Business Director in 2020. Recently, in 2021, they joined the American Lung Association in Michigan as a Member of the Board of Directors.
Jim Outlaw obtained an MBA degree from Eastern Michigan University from 2015 to 2017. Prior to that, they pursued a bachelor's degree in Business Administration with a focus on Business at Adrian College from 1998 to 2002, where they maintained an impressive 3.87 GPA.
This person is not in any teams
This person is not in any offices
Pulmonx
2 followers
Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1